# AGENUS INC (AGEN) — capital_raise/private_placement [announced]
Source: SEC API (secapi.ai) · situation sit_494a6399a94d1f9ff80f · retrieved 2026-08-12T07:00:15.121Z

## Overview
Agenus Inc. is a clinical-stage immuno-oncology company advancing a pipeline of antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the population of patients who may benefit from immunotherapy; its lead program is botensilimab plus balstilimab (BOT+BAL), a next-generation combination of a multifunctional, Fc-enhanced anti-CTLA-4 an…

Agenus Inc. completed an oversubscribed private placement in July 2026, raising approximately $85 million in upfront gross proceeds. The financing included milestone-aligned warrants that could provide up to approximately $255 million in additional gross proceeds if fully exercised. The upfront proceeds are expected to support ROBBIN initiation, regulatory alignment, and company operations through Q3 2027. Assuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031. ROBBIN is a planned global, randomized Phase 3 trial evaluating a short course of botensilimab (BOT) plus balstilimab (BAL) before surgery in approximately 850 previously untreated patients with high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer, with initiation and first patient dosing expected in the first quarter of 2027.

## Terms
- Deal value: $85.0M · Consideration: cash

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001193125-26-336780): 8-K - AGENUS INC — *Agenus Inc. is a clinical-stage immuno-oncology company advancing a pipeline of antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the population of patients who may benefit from immunotherapy; its lead program is botensilimab plus balstilimab (BOT+BAL), a next-generation combination of a multifunctional, Fc-enhanced anti-CTLA-4 an…* Agenus Inc. completed an oversubscribed private placement in July 2026, raising approximately $85 million in upfront gross proceeds. The financing included milestone-aligned warrants that could provide up to approximately $255 million in additional gross proceeds if fully exercised. The upfront proceeds are expected to support ROBBIN initiation, regulatory alignment, and company operations through Q3 2027. Assuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031. ROBBIN is a planned global, randomized Phase 3 trial evaluating a short course of botensilimab (BOT) plus balstilimab (BAL) before surgery in approximately 850 previously untreated patients with high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer, with initiation and first patient dosing expected in the first quarter of 2027.
  https://www.sec.gov/Archives/edgar/data/1098972/0001193125-26-336780.txt

## Citations
- 0001193125-26-336780 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526336780